Verve Therapeutics
Biotechnology company developing single-course in vivo gene editing medicines to durably lower blood lipids and reduce atherosclerotic cardiovascular disease (ASCVD) risk. The organization focuses on liver-directed gene inactivation informed by human genetics, with lead programs targeting PCSK9, ANGPTL3 and LPA and an emphasis on base editing and liver-targeted lipid nanoparticle delivery.
Industries
Nr. of Employees
large (251-1000)
Patents
Base editing of ANGPTL3 and methods of using same for treatment of disease
US-12115230-B2
View Details
Base editing of ANGPTL3 and methods of using same for treatment of disease
US-12115230-B2
View DetailsProducts
VERVE-102
An investigational single-course in vivo base editing medicine designed to inactivate the PCSK9 gene in the liver to reduce LDL-C; delivered via IV infusion using a GalNAc-LNP delivery system. Evaluated in Phase 1b Heart-2 study.
VERVE-201
A single-course base editing medicine designed to inactivate the ANGPTL3 gene in the liver to reduce LDL-C and triglycerides; uses a GalNAc-LNP delivery system and has demonstrated durable target protein reduction and lipid decreases in non-human primate studies.
VERVE-301
A research-stage, single-course gene editing program designed to inactivate the LPA gene in the liver to reduce circulating lipoprotein(a) and associated ASCVD risk; leverages GalNAc-LNP delivery.
VERVE-102
An investigational single-course in vivo base editing medicine designed to inactivate the PCSK9 gene in the liver to reduce LDL-C; delivered via IV infusion using a GalNAc-LNP delivery system. Evaluated in Phase 1b Heart-2 study.
VERVE-201
A single-course base editing medicine designed to inactivate the ANGPTL3 gene in the liver to reduce LDL-C and triglycerides; uses a GalNAc-LNP delivery system and has demonstrated durable target protein reduction and lipid decreases in non-human primate studies.
VERVE-301
A research-stage, single-course gene editing program designed to inactivate the LPA gene in the liver to reduce circulating lipoprotein(a) and associated ASCVD risk; leverages GalNAc-LNP delivery.
Expertise Areas
- Gene editing therapeutics for cardiovascular disease
- Base editing (adenine base editors)
- Liver-targeted delivery and LNP development
- Preclinical translational studies and NHP models
Key Technologies
- Base editing (adenine base editors)
- CRISPR-Cas9 (for model generation and editing)
- GalNAc-modified lipid nanoparticles (GalNAc-LNP)
- mRNA and guide RNA (gRNA) delivery